Histologic markers of inflammation in patients with ulcerative colitis in clinical remission

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 991-996

  Rosenberg, Laura ^a   Nanda, Kavinderjit S ^a   Zenlea, Talia ^a   Gifford, Anne ^a   Lawlor, Garrett O ^a   Falchuk, Kenneth R ^a   Wolf, Jacqueline L ^a   Cheifetz, Adam S ^a   Goldsmith, Jeffrey D ^a   Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

IBD; Mesalamine; Mucosal healing; Response to therapy; Therapeutic efficacy

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE;

ADULT; ARTICLE; ASCENDING COLON; BLOOD SAMPLING; CHEMICAL PARAMETERS; CLINICAL FEATURE; COLON BIOPSY; COLONOSCOPY; DISEASE SURVEILLANCE; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; REMISSION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; 6-MP; AZA; AZATHIOPRINE; C-REACTIVE PROTEIN; CRP; ERYTHROCYTE SEDIMENTATION RATE; ESR; IBD; MESALAMINE; MUCOSAL HEALING; RESPONSE TO THERAPY; THERAPEUTIC EFFICACY; UC; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERUM; SEVERITY OF ILLNESS INDEX;

EID: 84879225829     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.02.030     Document Type: Article

References (28)

1. Reinisch W., Van Assche G., Befrits R., et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012, 6:248-258.
2. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011, 5:477-483.
3. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
4. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
5. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
6. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
7. Hanauer S.B., Kirsner J.B. Treat the patient or treat the disease?. Dig Dis 2012, 30:400-403.
8. Wright R., Truelove S.R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966, 11:847-857.
9. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
10. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
11. Rubin D., Huo D., Hetzel J., et al. Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology 2012, 132:A19.
12. Burger D., Thomas S., Walsh A., et al. Depth of remission may not predict outcome of UC over 2 years. Gut 2011, 60:A133.
13. Geboes K., Riddell R., Ost A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
14. Baars J.E., Nuij V.J., Oldenburg B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012, 18:1634-1640.
15. Rosenberg L., Lawlor G.O., Zenlea T., et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2012, 19:779-784.
16. Thomas S., Von Herbay A., Walsh A. How much agreement is there between histological, endoscopic and clinical assessments of remission in ulcerative colitis?. Gut 2009, 58:A101.
17. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005, 54:782-788.
18. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
19. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
20. Bessissow T., Lemmens B., Ferrante M., et al. Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis patients with mucosal healing. Gastroenterology 2012, 142:S1-S653.
21. Moss A.C., Chaudhary N., Tukey M., et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis-a prospective study. J Crohns Colitis 2010, 4:171-175.
22. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
23. Baumgart D.C. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?. Dig Dis 2011, 29(Suppl 1):32-35.
24. D'Haens G., Geboes K., Peeters M., et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997, 92:1275-1279.
25. Mutinga M.L., Odze R.D., Wang H.H., et al. The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. Inflamm Bowel Dis 2004, 10:215-219.
26. Osada T., Ohkusa T., Okayasu I., et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008, 23(Suppl 2):S262-S267.
27. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
28. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.